High-Throughput Screening
This service allows researchers to perform high throughput screens to identify novel treatments for cancer and other diseases.
About
The ANU Centre for Therapeutic Discovery (ACTD) includes state-of-the-art robotic and liquid handling systems that will allow researchers to perform high throughput screens to identify novel treatments for cancer and other diseases. This facility is the first of its kind in the ACT, bringing ANU in line with other world-class research institutes around Australia. It is comprised of two separate workstations: a high throughput screening workstation and a high content/imaging workstation. Both of these workstations are equipped with robotic arms and liquid handling instruments that will allow researchers to perform a variety of different tasks (e.g. seeding cells into microplates and performing drug treatments) on a large scale. Access to robotics to perform these tasks reduces the time it takes to undertake these large-scale experiments, thus significantly speeding up the target discovery process.
Projects using this platform can lead to:
- Finding new therapeutic targets
- Repurposing existing drugs to treat other diseases
- Identifying drug combinations and synergies to optimise treatment
- Understanding cancer cell biology
- Providing a platform for discovery and early development of novel biologically active compounds to treat human disease
Services
The ACTD onsells automation consumables such as tips, microplates (96, 384, 1536), tissue culture consumables, screening reagents, transfection reagents and more.
Through close collaboration, we adopt assays established in your laboratory and make them amenable for boutique and large scale high-throughput screening.
Our automation and liquid handling services streamline laboratory workflows by increasing precision, reproducibility and enhancing efficiency in high-throughput processes.
High-throughput compound screening evaluates large libraries of chemical compounds to discover candidates for the development of new treatments and therapies.
CRISPR screening systematically modifies genes across a genome, enabling researchers to identify genes that are crucial for specific cellular functions or disease processes.
High-throughput flow cytometry enables the rapid, multiparametric analysis of thousands of cells for large-scale screening and detailed cellular characterization in drug discovery and immunology.
Organoids and spheroids mimic the architecture and function of tissues, making them valuable tools in high-throughput 3D screening for drug discovery and disease modeling.
RNA interference (RNAi) screening is a technique used to knock down specific genes to study their function and identify potential therapeutic targets.
Both of these workstations are equipped with robotic arms and liquid handling instruments that will allow researchers to perform a variety of different tasks (e.g. seeding cells into microplates and performing drug treatments) on a large scale.